

Ship to: Patient Physician Other Need: Nurse Training
All supplies, including syringes and needles, will be dispensed if needed.

Patient Information	Patient Name: _____ DOB: _____ SSN: _____
	Address: _____
	City: _____ State: _____ Zip: _____
	Phone: _____ Alt Phone: _____
	Email: _____
	Alternate Contact Info: _____
	Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female Allergies: _____

PLEASE ATTACH COPIES OF FRONT AND BACK OF PATIENT'S PRESCRIPTION INSURANCE CARDS AND MOST RECENT LABS

Clinical Information	Diagnosis: Date of Diagnosis: _____ <input type="checkbox"/> J82 Pulmonary Eosinophilia <input type="checkbox"/> J45.40 Moderate Persistent Asthma, uncomplicated <input type="checkbox"/> J45.50 Severe Persistent Asthma, uncomplicated <input type="checkbox"/> Other Diagnosis: ICD-10 Code _____	FEV1 _____%	Pre-treatment IgE: <input type="checkbox"/> <30IU/ml <input type="checkbox"/> ≥30-100IU/ml <input type="checkbox"/> >100-200IU/ml <input type="checkbox"/> >200-300IU/ml <input type="checkbox"/> >300-400IU/ml <input type="checkbox"/> >400-500IU/ml <input type="checkbox"/> >500-600IU/ml <input type="checkbox"/> >600-700IU/ml
	Description: _____	Patient medical history includes: <input type="checkbox"/> Positive RAST <input type="checkbox"/> Positive skin test to perennial aeroallergen <input type="checkbox"/> Asthma with eosinophilic phenotype <input type="checkbox"/> Other: _____	
	Current Maintenance Treatment (include dose and frequency): _____		
	Current Exacerbation Treatment (include dose and frequency): _____		
	Prior Therapy: _____	Approx Start Date: _____	
	Reason for Discontinue Therapy: _____	Approx Stop Date: _____	
Comorbidities: _____			
Concomitant Medications: _____			

Prescription Information	Medication	Strength	Directions	Quantity	Refills
<input type="checkbox"/> Dupixent		<input type="checkbox"/> 300mg/2ml PF Syringe <input type="checkbox"/> 300mg/2ml PF Pen <input type="checkbox"/> 200mg/1.14ml PF Syringe <input type="checkbox"/> 200mg/1.14ml PF Pen	For Adult and Pediatric Patients 12 years and older with Asthma <u>Initial Dosing:</u> <input type="checkbox"/> Inject 400mg (two 200mg injections) SQ at week 0 <input type="checkbox"/> Inject 600mg (two 300mg injections) SQ at week 0 <u>Subsequent Dosing:</u> <input type="checkbox"/> Inject 200mg SQ every 2 weeks starting at week 2 <input type="checkbox"/> Inject 300mg SQ every 2 weeks starting at week 2	2 2 2 2	None None _____ _____
			For Patients with Oral Corticosteroid-Dependent Asthma or Adults with Co-Morbid Chronic Rhinosinusitis with Nasal Polyposis <u>Initial Dosing:</u> <input type="checkbox"/> Inject 600mg (two 300mg injections) SQ at week 0 <u>Subsequent Dosing:</u> <input type="checkbox"/> Inject 300mg SQ every 2 weeks starting at week 2	2 2	None _____

Referral form continued on the next page

Prescription Information	<input type="checkbox"/> Fasentra	<input type="checkbox"/> 30mg/mL PF Syringe <input type="checkbox"/> 30mg/mL PF Pen	For Asthma: <input type="checkbox"/> Initial Dose: 30mg subcutaneously every 4 weeks for 3 doses <input type="checkbox"/> Maintenance: 30mg subcutaneously every 8 weeks	1 1	2 _____
	<input type="checkbox"/> Nucala	<input type="checkbox"/> 100mg/ml PF Autoinjector <input type="checkbox"/> 100mg/ml PF Glass Syringe <input type="checkbox"/> 40mg/0.4ml PF Glass Syringe	For Adult and Adolescent Patients 12 years and older <input type="checkbox"/> Inject 100mg SQ every 4 weeks into the upper arm, thigh, or abdomen	1	_____
			For Pediatric Patients Aged 6 to 11 years <input type="checkbox"/> Inject 40mg SQ every 4 weeks into the upper arm, thigh, or abdomen	1	_____
	<input type="checkbox"/> Xolair	<input type="checkbox"/> 75mg/0.5mL PF Syringe <input type="checkbox"/> 150mg/mL PF Syringe <input type="checkbox"/> 150mg Vial	For Asthma <input type="checkbox"/> _____mg (150mg to 375mg) subcutaneously every _____ weeks	_____	_____
<input type="checkbox"/> Other: _____				_____	_____

Prescriber Information	PRIOR AUTHORIZATION	
	Prescriber Name: _____	NPI: _____ DEA: _____ LIC#: _____
	Address: _____	
	City: _____	Zip: _____ Tel: _____ Fax: _____
	Contact Person: _____	E-Mail: _____
PRESCRIBER SIGNATURE		
(Prescriber, please sign and date below)		
No stamps. Signature and date must be completed in prescriber's handwriting. NY prescriptions must be submitted via e-script.		
I authorize Polaris Specialty Pharmacy and its representatives to act as an agent to initiate and execute prior authorization for the above patient. In order to expedite the process, please provide chart notes and most recent labs.		
Physician's Signature: _____ <input type="checkbox"/> Dispense as written (DAW) Date: ____/____/____		
<small>IMPORTANT NOTICE: This communication is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient, employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination, distribution, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone.</small>		

Intentionally left blank